Dupont Capital Management Corp acquired a new position in Mallinckrodt PLC (NYSE:MNK) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 11,000 shares of the company’s stock, valued at approximately $322,000.

A number of other hedge funds have also recently modified their holdings of MNK. Advisors Preferred LLC lifted its holdings in Mallinckrodt by 493.9% in the 2nd quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock worth $196,000 after buying an additional 8,742 shares in the last quarter. Balasa Dinverno & Foltz LLC acquired a new stake in shares of Mallinckrodt in the 2nd quarter valued at about $200,000. Janus Henderson Group PLC acquired a new stake in shares of Mallinckrodt in the 2nd quarter valued at about $237,000. Bronfman E.L. Rothschild L.P. raised its stake in shares of Mallinckrodt by 46.7% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 15,238 shares of the company’s stock valued at $284,000 after purchasing an additional 4,853 shares in the last quarter. Finally, Hartford Investment Management Co. acquired a new stake in shares of Mallinckrodt in the 2nd quarter valued at about $293,000.

Shares of NYSE:MNK opened at $26.30 on Thursday. The company has a quick ratio of 2.05, a current ratio of 2.21 and a debt-to-equity ratio of 0.93. Mallinckrodt PLC has a fifty-two week low of $11.65 and a fifty-two week high of $36.65. The stock has a market cap of $2.57 billion, a P/E ratio of 3.51, a price-to-earnings-growth ratio of 0.41 and a beta of 1.71.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.31. Mallinckrodt had a net margin of 65.24% and a return on equity of 9.60%. The business had revenue of $640.00 million during the quarter, compared to the consensus estimate of $634.38 million. During the same quarter in the prior year, the firm earned $1.97 EPS. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. On average, equities analysts expect that Mallinckrodt PLC will post 7.09 earnings per share for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. B. Riley upped their target price on shares of Mallinckrodt from $20.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 24th. Zacks Investment Research upgraded shares of Mallinckrodt from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Monday, August 27th. Wells Fargo & Co restated a “hold” rating on shares of Mallinckrodt in a research note on Wednesday, August 22nd. Canaccord Genuity set a $34.00 target price on shares of Mallinckrodt and gave the company a “hold” rating in a research note on Sunday, August 19th. Finally, Morgan Stanley upped their target price on shares of Mallinckrodt from $14.00 to $35.00 and gave the company an “equal weight” rating in a research note on Friday, August 17th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $33.00.

ILLEGAL ACTIVITY WARNING: “11,000 Shares in Mallinckrodt PLC (MNK) Purchased by Dupont Capital Management Corp” was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/22/11000-shares-in-mallinckrodt-plc-mnk-purchased-by-dupont-capital-management-corp.html.

Mallinckrodt Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Featured Story: What is a Fiduciary?

Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).

Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.